Publications by authors named "Narasimha Marella"
Article Synopsis
- Richter transformation is a serious form of aggressive lymphoma found in about 10% of chronic lymphocytic leukemia patients, with no approved treatments and a grim outlook.
- Pirtobrutinib, showing good results for patients with B-cell malignancies who have relapsed or are resistant to conventional therapies, is being studied for its safety and effectiveness in treating Richter transformation.
- The study included 82 adult patients who received pirtobrutinib daily, tracking overall response rates and safety, with results indicating the drug was well tolerated and active in this difficult subset of cancer patients.
Article Synopsis
- Pirtobrutinib, a selective noncovalent Bruton tyrosine kinase inhibitor, was tested in a phase 1b trial for patients with relapsed or refractory chronic lymphocytic leukemia (CLL) using combinations of pirtobrutinib and venetoclax, with some patients also receiving rituximab.
- The trial showed high overall response rates of 93.3% for the pirtobrutinib plus venetoclax group and 100% for the group including rituximab, with significant percentages achieving undetectable minimal residual disease after 12 cycles of treatment.
- Common adverse effects included neutropenia and anemia, but treatment was well tolerated, and almost all
Context.—: RET gene fusions are oncogenic drivers in nonsmall cell lung cancer and nonmedullary thyroid cancer. Selpercatinib (RETEVMO), a targeted inhibitor of RET, was approved by the US Food and Drug Administration for the treatment of RET fusion-positive nonsmall cell lung cancer and nonmedullary thyroid cancer emphasizing the need for rapid and accurate diagnosis of RET fusions.
View Article and Find Full Text PDFBackground: Targeted sequencing using oncopanels requires comprehensive assessments of accuracy and detection sensitivity to ensure analytical validity. By employing reference materials characterized by the U.S.
View Article and Find Full Text PDFCirculating tumor DNA (ctDNA) sequencing is being rapidly adopted in precision oncology, but the accuracy, sensitivity and reproducibility of ctDNA assays is poorly understood. Here we report the findings of a multi-site, cross-platform evaluation of the analytical performance of five industry-leading ctDNA assays. We evaluated each stage of the ctDNA sequencing workflow with simulations, synthetic DNA spike-in experiments and proficiency testing on standardized, cell-line-derived reference samples.
View Article and Find Full Text PDFArticle Synopsis
- Covalent BTK inhibitors are effective for B-cell malignancies, but patients often stop using them due to resistance or side effects, prompting the evaluation of pirtobrutinib, a new reversible BTK inhibitor.
- In a phase 1/2 trial with 323 patients, pirtobrutinib showed no dose-limiting toxicities and the recommended dose was established at 200 mg daily, with some reported side effects like fatigue and diarrhea.
- Among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who previously used other BTK inhibitors, pirtobrutinib demonstrated a 62% overall response rate, indicating significant efficacy even in those who previously experienced treatment resistance or intolerance.*